Ovid Therapeutics (OVID) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Ovid Therapeutics (OVID) is Neutral.

The composite score behind that read is -0.03, weighing +0.02 of bullish evidence against -0.24 bearish.

Ovid Therapeutics last closed at $2.46, +5.13% on the session.

Against the IVW growth benchmark the position is +4.33% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

3 graded predictions for OVID so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Ovid Therapeutics in the 26th percentile on return on equity, where 100 is best.

Ovid Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $457.00M.

StockMap tracks Ovid Therapeutics as the 184th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Ovid Therapeutics ranks 133rd of 381 in the group, against a group median of -0.08.